

Universität Ulm | 89069 Ulm | Germany

Medizinische Fakultät Institut für Epidemiologie und Medizinische Biometrie Leitung: Prof. Dr. D. Rothenbacher http://www.uni-ulm.de/med/epidemiologie-biometrie

Prof. Rainer Muche Schwabstraße 13 89075 Ulm, Germany

Dr. Kathrin Hohl <u>k\_koetting@web.de</u> PD Dr. Benjamin Mayer <u>benjamin.mayer@uni-ulm.de</u>

29-NOV-2017

#### **Module: Clinical Trials**

General information:

Week 1 (DEC 4 <sup>th</sup> – DEC 8 <sup>th</sup> ):	
Week 2 (DEC 13 <sup>th</sup> and DEC 15 <sup>th</sup> ):	

Lectures Mon-Fri 8.30am - 10.00am and 10.30 - 11.45am Case-study presentations on Wednesday 8.30am - 12.00pm Written exam on Friday 10am - 11am

Rooms:	Mo 4 <sup>th</sup> , Tue 5 <sup>th</sup> , Wed 6 <sup>th</sup> , Thu 7 <sup>th</sup> :	<b>O29/1</b> 001
	Fri 8 <sup>th</sup> :	N23/2622
	Wed 13 <sup>th</sup> (students' talks):	<b>O29/1</b> 001
	Fri 15 <sup>th</sup> (exam):	O23/2611

#### Course material online:

http://www.uni-ulm.de/med/epidemiologie-biometrie/lehre/molekularmedizin/mol-clinical-trials.html

#### Lecture content:

#### Monday, Dec 4th, 2017:

*Introduction, Course schedule, What is a clinical trial? Dr. Kathrin Hohl* Overview of the Module, assigning topics to groups for presentation Aims, concept, fundamentals of clinical trials

#### Planning a Study and Recruitment of study participants Dr. Kathrin Hohl

Phases of clinical trials, Study protocol, Statistical hypotheses, sample size, randomisation



# ulm university universität **UUUIM**

#### Tuesday, Dec 5th, 2017:

Regulatory aspects conducting a clinical trial

#### Dr. Kathrin Hohl

Study documents (Trial Master File) Responsibilities and tasks of people and institutions involved in clinical trials Official rules for clinical trials (Guidelines): ICH-GCP, Declaration of Helsinki, AMG

# Data collection and Quality Control PD Dr. Benjamin Mayer

Types of data and their recording (Case Report Forms) Data Management, Data Checks and correction (audit trail) Database: structure and design, database-close and data release Software for data and project management in clinical trials (e.g. audit trail) Coding of Adverse events and concomitant medication Quality assurance: Monitoring, Audits

#### Wednesday, Dec 6<sup>th</sup>, 2017:

#### Analyzing a Study and Issues in Data Analysis (I)

#### PD Dr. Benjamin Mayer

Statistical considerations (ICH E9) Special Issues:

- Analysis populations (Full Sample Analysis, Per Protocol Analysis),
- missing values
- graphical presentations

#### Analyzing a Study and Issues in Data Analysis (II)

#### PD Dr. Benjamin Mayer

Statistical considerations (ICH E9) Special Issues:

- adjustment for confounder
- subgroup analysis
- multiple testing





### Thursday, Dec 7<sup>th</sup>, 2017:

Reporting and Interpreting the Study Results Dr. Kathrin Hohl ICH-E3: Structure and content of Clinical Study Reports Description of patients in the study (external validity) and comparability of groups (internal validity) Efficacy, safety (unexpected events, laboratory measures) Explorative data analysis (EDA), sources of bias

#### Assessing publications

*Dr. Kathrin Hohl* Assessing publication based on study design, validity of results, presentation of results

#### Friday, Dec8th, 2017:

Scientific appraisal of clinical trial reports PD Dr. Benjamin Mayer PICO assessment (Population, Intervention, Control, Outcome) Clinical trial registries and the ALLTRIALS initiative Medical science in the public press

#### Beyond the individual clinical trial

*PD Dr. Benjamin Mayer* Planning drug development Systematic reviews for Evidence Based Medicine Forest plot and Funnel plot

<u>Wednesday, Dec 13<sup>th</sup>, 2017, 8:30 – 11:45 am:</u> CASE-Study presentations: Dr. Kathrin Hohl & PD Dr. Benjamin Mayer Student presentations (all groups) All presentations need to be uploaded to the course homepage prior to presentation

<u>Friday, Dec 15<sup>th</sup>, 2017; 10 – 11 am:</u> Written examination: Dr. Kathrin Hohl & PD Dr. Benjamin Mayer

## Examination

The examination of the course is based on the following:

- **Oral presentation** on 13-DEC-2017 (see next page), and the upload of the group's presentation (25% of the final mark)
- Written test on 15-DEC-2017 (75% of the final mark)



# **Student presentations**

Group	1 <sup>st</sup> round, groups 1-3	2 <sup>nd</sup> round, groups 4-5
	(13-DEC-2017, 8.30am - 10.00am)	(13-DEC-2017, 10.30am - 12.00pm)
1	<ul> <li>TGN 1412: Overview on drug &amp; trial</li> <li>Drug properties and planning of the trial</li> <li>Conduct and results</li> <li>Interpretations and discussions</li> </ul>	
2	<ul> <li>Implications of BIA 10–2474 clinical trial</li> <li>What happened, why?</li> <li>Implications for FIM</li> </ul>	
3	Dabigatran <ul> <li>RE-LY study</li> <li>Different indications</li> <li>Dabigatran reversal</li> </ul>	
4		<ul> <li>CAPRIE: Treatment effect in subgroups</li> <li>Homogeneity in subgroups</li> <li>ICH E9</li> </ul>
5		<ul><li>Drug transporter studies</li><li>Overview on published studies</li><li>Results of patient trials in detail</li></ul>

Each group consists of 4-5 students.

Each student presents 5 min on its own as part of the group's presentation.

All presentations need to be uploaded to the course homepage, the names of all group members shall be given on the title page. For the upload of student presentations, please contact *iris.lichtblau@uni-ulm.de* or *bettina.mack@uni-ulm.de*.



Title of Module: Aspects of Molecular Medicine				
	Title: Clinical Trials			
Course	Number: MOMEm0070			
Study Programme:	Master degree in Molecular Medicine			
Responsible Lecturer:	Prof. Dr. Rainer Muche			
Eurther Lecturers:	Dr. Kathrin Hohl, PD Dr. Benjamin Maver			
Study Objectives:	<ul> <li>Students should</li> <li>Know the general outline of pre-clinical and clinical drug development</li> <li>Identify trial phases of the development of drugs</li> <li>Summing up the main steps in planning, conducting, monitoring and reporting clinical trials and their objectives</li> <li>Distinguish prospective and retrospective studies</li> <li>Identify the clinical trial protocol as the main source for planning, conducting and reporting</li> <li>Provide the importance of randomization and blinding to ensure the structural and observational equality of the treatment groups</li> <li>Know different types of randomization techniques</li> <li>Know the CRF as the basis of data collection</li> <li>Provide reasoning for prospectively planning the statistical analysis</li> <li>Discuss the importance of the ITT analysis</li> <li>Describe the PICO system to critically appraise reports of trials</li> <li>Find studies in clinical trial registries (ISRCTN, clinicaltrials.gov etc.)</li> </ul>			
Module Contents:	<ul> <li>Name measures for quality assurance</li> <li>Planning a trial</li> <li>Aspects of performing a trial</li> <li>Aspects of data management and analysis of trials</li> <li>Reporting and appraising clinical trials</li> <li>Application to examples in early clinical trials</li> </ul>			
Literature:	<ul> <li>L.M. Friedman, C.D. Furberg, D.L. DeMets: Fundamentals of Clinical Trials (5th Ed.). Springer, New York, 2015</li> <li>Wang D, Bakhai A. Clinical Trials - A Practical Guide to Design, Analysis, and Reporting. Remedica Publishing. 2006</li> <li>D. Machin, M.J. Campbell. Design of studies for medical research, Wiley 2005</li> <li>K.F. Schulz, D.G. Altman, D. Moher: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332</li> </ul>			
Classification:	Compulsory course			
Prerequisites:	BSc degree in Life Sciences			
Teaching methods:	Lecture, seminar			
Examinations:	<ul><li> 1 group presentation</li><li>Written examination</li></ul>			
ECTS-Points:	5			
Grade composition:	Written examination 75%, presentation 25%			
Length of the Module:	2 weeks (in blocks)			
Usability:	MSc course of studies Molecular Medicine, interested PhD students			
Date and Capacity:	30 students per semester			
Semester	Winter term			